During the 25th annual H.C. Wainwright Global Investment Conference, Biophytis’ CEO Stanislas Veillet presented the company, its ambitions and the latest progress it made on its various projets. A replay will be available for 90 days at the following link: https://journey.ct.events/view/1037e68b-3f79-4b25-9a15-27affba4d7c4 Watch here
Decoding #BIOTECH on Maddyness Read in French “Covid-19 : ces BioTech françaises engagées dans la course aux traitements” Read article in French on www.maddyness.com
Biophytis hosted a virtual key opinion leader (KOL) event on October 6th, 2021, on its lead projects, Sarconeos (BIO101) for the treatment of COVID-19 and Sarcopenia
Stanislas Veillet tells us in video on the active preparation of the marketing of Sarconeos for the first half of 2022
Stanislas Veillet, CEO of Biophytis, reviews the company’s latest news in this interview with Laurent Grassin from Journal des Biotechs, covering listing on Nasdaq, Covid-19 clinical studies, expected clinical data in sarcopenia and the legal case with Negma.
Interview of Stanislas Veillet, CEO of Biophytis on Les Pros de l’Eco (in French)
Interview of Stanislas Veillet, CEO of Biophytis on the Grand Angle – TV5 Monde (in French)
Interview of Stanislas Veillet, CEO of Biophytis by Didier Testot on the web Tv